Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4681-4697
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4681
Table 1 Detailed clinical characteristics of 483 patients with portal hypertension
VariableTraining cohort
Validation cohort
Without PVT (n = 203)
PVT (n =135)
P value
Without PVT (n = 80)
PVT (n = 65)
P value
Sex, n (%)0.3120.86
Female69 (34.0)38 (28.1)20 (25.0)18 (27.7)
Male134 (66.0)97 (71.9)60 (75.0)47 (72.3)
Age, n (%)0.1790.999
< 60 yr165 (81.3)118 (87.4%)71 (88.8)58 (89.2)
≥ 60 yr38 (18.7)17 (12.6%)9 (11.2)7 (10.8)
Smoking, n (%)0.7030.983
No167 (82.3)108 (80.0)64 (80.0)51 (78.5)
Yes36 (17.7)27 (20.0)16 (20.0)14 (21.5)
Alcohol, n (%)0.5770.587
No167 (82.3)115 (85.2)69 (86.2)53 (81.5)
Yes36 (17.7)20 (14.8)11 (13.8)12 (18.5)
RBC1 (× 1012/L)3.59 (3.20-3.93)3.57 (3.21-3.90)0.693.74 (3.49-4.02)3.55 (3.22-3.93)0.044
HLB1 (g/L)89.3 (78.1-103)93.2 (82.1-104)0.09389.5 (79.5-107)91.1 (82.8-101)0.965
WBC1 (× 109/L)2.51 (1.83-3.40)2.18 (1.48-2.87)0.0072.46 (1.95-3.21)2.09 (1.58-2.92)0.06
N1 (× 109/L)1.35 (0.98-2.09)1.27 (0.85-2.00)0.1771.38 (1.06-1.98)1.15 (0.87-1.77)0.147
L1 (× 109/L) 0.79 (0.56-1.14)0.50 (0.38-0.79)< 0.0010.78 (0.51-1.11)0.63 (0.45-0.91)0.045
NLR11.78 (1.18-2.99)2.43 (1.42-4.18)0.0031.90 (1.23-3.08)2.16 (1.39-3.16)0.559
PLT1 (× 109/L) 48.0 (36.0-64.5)33.8 (26.0-47.9)< 0.00146.0 (32.1-57.0)35.0 (27.0-48.0)0.012
PLR160.6 (43.4-97.0)72.5 (35.0-99.7)0.77955.6 (37.9-91.3)58.8 (31.8-86.8)0.692
PT1 (s) 15.5 (14.1-16.6)15.3 (12.9-16.4)0.22115.7 (14.4-16.3)15.3 (13.9-16.2)0.294
PTA1 (%) 64.0 (57.0-73.5)60.0 (50.0-69.0)< 0.00167.0 (57.0-73.0)63.0 (54.0-72.0)0.269
INR11.34 (1.23-1.47)1.42 (1.29-1.62)< 0.0011.32 (1.23-1.50)1.36 (1.23-1.50)0.519
FIB1 (g/L)2.35 (1.62-3.86)2.52 (1.82-3.78)0.2692.29 (1.74-4.14)2.57 (1.83-3.62)0.764
APTT1 (s)40.7 (37.5-44.8)40.6 (36.9-44.9)0.78741.3 (37.9-44.3)41.0 (38.5-44.1)0.822
ALT1 (U/L)22.0 (16.0-30.5)21.0 (15.0-28.0)0.57825.5 (17.8-40.0)18.0 (15.0-27.0)0.007
AST1 (U/L)29.0 (22.0-40.0)25.0 (22.0-35.0)0.02130.5 (24.8-43.5)25.0 (21.0-34.0)0.009
ALB1 (g/L) 35.9 (32.7-39.5)35.8 (32.6-39.5)0.88135.7 (33.1-38.3)36.4 (33.7-39.6)0.551
TBIL1 (μmol/L)18.1 (12.4-24.6)18.8 (12.4-27.0)0.67118.8 (13.6-24.6)18.0 (14.4-26.1)0.796
Child-Pugh grade, n (%)0.6440.999
A146 (71.9)101 (74.8)58 (72.5)48 (73.8)
B57 (28.1)34 (25.2)22 (27.5)17 (26.2)
EGV, n (%)0.0230.001
No67 (33.0)62 (45.9)17 (21.2)32 (49.2)
Yes136 (67.0)73 (54.1)63 (78.8)33 (50.8)
SPT1 (cm)5.50 (4.60-6.40)6.40 (5.40-7.55)< 0.0015.70 (4.45-6.70)6.30 (5.30-7.30)0.034
DPV1 (cm)1.30 (1.10-1.40)1.50 (1.25-1.70)< 0.0011.30 (1.10-1.50)1.40 (1.20-1.60)0.088
PBT, n (%)0.1260.023
No159 (78.3)95 (70.4)67 (83.8)43 (66.2)
Yes44 (21.7)40 (29.6)13 (16.2)22 (33.8)
De, n (%)0.4570.344
No16 (7.88)7 (5.19)4 (5.00)6 (9.23)
Yes187 (92.1)128 (94.8)76 (95.0)59 (90.8)
PLT11 (× 109/L)79.0 (61.0-106)79.0 (64.0-102)0.86674.0 (57.7-93.8)77.0 (61.0-102)0.418
PLT31 (× 109/L)103 (78.5-158)117 (85.0-164)0.13198.5 (75.5-140)112 (81.0-156)0.122
PPER11 (%)0.59 (0.34-0.88)1.18 (0.57-2.31)< 0.0010.70 (0.36-1.11)0.87 (0.64-2.03)0.002
PPER31 (%)1.15 (0.62-2.02)2.38 (1.52-3.87)< 0.0011.32 (0.79-2.04)2.29 (1.36-3.54)< 0.001
Table 2 Univariate and multivariate logistic regression analyses for risk factors associated with portal vein thrombosis in the overall cohort
VariableUnivariate
Multivariate1
OR (95%CI)
P value
OR (95%CI)
P value
Sex (female vs male)1.18 (0.79-1.76)0.42
Age (< vs ≥ 60 yr)0.68 (0.40-1.16)0.16
Smoking (no vs yes)1.15 (0.73-1.81)0.56
Alcohol (no vs yes)0.96 (0.59-1.56)0.86
RBC2 (× 1012/L)0.71 (0.44-1.14)0.16
HLB2 (g/L)1.01 (0.99-1.02)0.22
WBC2 (× 109/L)0.87 (0.76-1.00)0.05
N2 (× 109/L)1.05 (0.98-1.12)0.20
L2 (× 109/L)0.27 (0.16-0.45)< 0.0010.28 (0.14-0.54)< 0.001
NLR21.07 (1.01-1.14)0.031.03 (0.98-1.11)0.42
PLT2 (× 109/L)0.98 (0.97-0.99)< 0.0010.99 (0.98-1.01)0.98
PLR21.00 (1.00-1.00)0.18
PT2 (s) 0.94 (0.89-1.00)0.07
PTA2 (%)0.97 (0.96-0.99)< 0.0010.99 (0.98-1.02)0.73
INR20.98 (0.88-1.09)0.74
FIB2 (g/L) 1.06 (0.93-1.21)0.42
APTT2 (s)0.99 (0.96-1.01)0.38
ALT2 (U/L)0.99 (0.98-1.00)0.16
AST2 (U/L)0.98 (0.97-0.99)< 0.0010.99 (0.98-1.00)0.14
ALB2 (g/L) 1.00 (0.97-1.04)0.97
TBIL2 (μmol/L)1.00 (0.99-1.02)0.78
Child-Pugh (A vs B)0.88 (0.59-1.33)0.56
EGV (no vs yes)0.48 (0.33-0.69)< 0.0010.51 (0.32-0.79)0.003
SPT2 (cm)1.34 (1.19-1.50)< 0.0011.22 (1.06-1.40)0.005
DPV2 (cm)4.72 (2.69-8.29)< 0.0013.57 (1.86-7.03)< 0.001
PBT (no vs yes)1.78 (1.17-2.70)0.011.33 (0.79-2.26)0.28
De (no vs yes)1.09 (0.53-2.25)0.81
PLT12 (× 109/L)1.00 (0.99-1.00)0.32
PLT32 (× 109/L)1.00 (1.00-1.00)0.25
PPER2 (%)2.77 (2.1-3.66)< 0.0011.78 (1.24-2.62)0.002
PPER32 (%)1.86 (1.58-2.19)< 0.0011.43 (1.16-1.77)< 0.001
Table 3 Performance of models for portal vein thrombosis risk prediction in different cohorts

AUC (95%CI)
Sensitivity (95%CI)
Specificity (95%CI)
PPV (95%CI)
NPV (95%CI)
Accuracy (%)
F1
Kappa
Brier
Overall cohort
GLM0.812 (0.773-0.851)0.710 (0.642-0.772)0.799 (0.747-0.844)0.714 (0.650-0.775)0.796 (0.740-0.841)76.20.7120.5090.169
LSM0.822 (0.784-0.861)0.640 (0.569-0.706)0.869 (0.824-0.906)0.776 (0.709-0.824)0.774 (0.718-0.832)77.40.7010.5220.163
RFM0.814 (0.775-0.854)0.665 (0.595-0.730)0.852 (0.805-0.891)0.760 (0.695-0.812)0.782 (0.727-0.837)77.40.7090.5260.168
Training cohort
GLM0.833 (0.787-0.879)0.674 (0.588-0.752)0.877 (0.824-0.919)0.784 (0.705-0.842)0.802 (0.736-0.865)79.60.7250.5640.157
LSM0.839 (0.794-0.884)0.733 (0.650-0.806)0.828 (0.768-0.877)0.739 (0.662-0.810)0.824 (0.759-0.874)79.00.7360.5620.153
RFM0.838 (0.793-0.883)0.756 (0.674-0.825)0.808 (0.747-0.860)0.723 (0.647-0.800)0.832 (0.769-0.879)78.70.7390.5590.154
Validation cohort
GLM0.769 (0.691-0.846)0.646 (0.518-0.761)0.825 (0.724-0.901)0.750 (0.625-0.839)0.742 (0.628-0.847)74.50.6940.4770.190
LSM0.826 (0.755-0.897)0.708 (0.582-0.814)0.863 (0.767-0.929)0.807 (0.687-0.883)0.784 (0.676-0.884)79.30.7540.5770.163
RFM0.777 (0.700-0.853)0.631 (0.502-0.747)0.875 (0.782-0.938)0.804 (0.678-0.876)0.745 (0.632-0.864)76.60.7070.5160.187